A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H, et al. Br J Haematol. 2011 Nov; 155(4):426-37. Epub 2011 Sep 09. PMID: 21902688. Abstract CommentRecommendBookmarkWatch